Articles tagged with Dopaminergic Neurons
Researchers have identified a key defect in ER-to-Golgi trafficking that contributes to alpha-synuclein toxicity, a hallmark of Parkinson's disease. Enhancing this pathway may suppress alpha-synuclein toxicity and protect dopamine-producing neurons.
Researchers discovered that nicotine activates specific receptors in dopamine-producing neurons, leading to increased responsiveness and triggering exploratory behaviors. The study suggests a hierarchical role of two receptor subunits in regulating the response to nicotine.
UB researchers have discovered an agent, L-AP4, that activates group III metabotropic glutamate receptors and reverses damage caused by rotenone. The findings could lead to a new treatment for Parkinson's disease.
Pitt researchers identify critical brain area regulating dopamine function, which could explain disruptions in normal behaviors and psychiatric disorders like schizophrenia and drug addiction. The discovery provides new insights into the brain's reward system and its role in modulating goal-directed behavior.
Researchers found that male-specific gene SRY is required for normal brain function of dopamine-secreting neurons. This may help explain the higher incidence of Parkinson's disease in males, which exhibits a 3:2 ratio with females.
A master determinant was identified to generate dopamine neurons from embryonic stem cells, promising advances in cell replacement therapy for Parkinson's disease. The discovery also highlights the importance of understanding developmental processes for producing authentic cells from stem cells.
Lorraine Iacovitti and her team have created a quicker method using defined additives from human origin to differentiate human embryonic stem cells into dopamine-producing neurons in three weeks. This new approach aims to reduce the risk of immune rejection by eliminating animal-derived substances.
Researchers created an animal model of Parkinson's disease using fruit flies with deleted DJ-1 genes, finding increased sensitivity to oxidative damage from common agricultural agents. The study suggests that DJ-1 plays a critical role in protecting dopaminergic neurons from oxidative stress.
Researchers at the University at Buffalo have identified microtubules as a critical target for treating Parkinson's disease, which is caused by damage to these intracellular highways. The study found that protecting microtubules can prevent the toxic effects of rotenone on dopamine-producing neurons.
Researchers discovered that BAG5 protein enhances dopaminergic neuron death and inhibits parkin activity, leading to increased neuronal death. Inhibiting BAG5 increases neuronal survival, suggesting a potential therapeutic target for neurodegenerative diseases like Parkinson's.
Researchers found that mutated parkin genes combined with rotenone damage microtubules, disrupting dopamine transport and causing free radical release. This study may lead to novel therapies for Parkinson's disease by stabilizing microtubules against pesticide toxins.
Researchers found that viral delivery of a parkin gene protected dopamine-producing neurons from degeneration, offering new hope for treating Parkinson's disease. The study demonstrates the feasibility of gene therapy in a genetic model of the disease.
Researchers at Thomas Jefferson University have successfully converted adult human bone marrow stem cells into functional dopamine neurons using a novel growth factor-based approach. The newly differentiated cells expressed key markers of dopamine-producing cells and produced essential enzymes, offering a promising source for treating ...
Chronic exposure to pesticides like rotenone has been linked to Parkinson's disease pathology in monkeys. Exercise has shown potential in protecting against dopamine neuron loss and slowing disease progression in rats. Rotigotine, a new drug, may also offer neuroprotective properties.
A study in rats found that exercising limbs can protect brain cells from degeneration caused by Parkinson's disease. Exercise was shown to increase the production of key proteins that promote neuronal survival, such as glial cell line-derived neurotropic factor (GDNF), which may help offset cell vulnerability to oxidative stress.
The grant will fund research on dopamine neurons and brain adaptation in Parkinson's disease, with the goal of developing new treatments for patients. Northwestern University's expertise in neuroscience and molecular imaging will be utilized in this effort.
Researchers at Columbia University Irving Medical Center discovered that mutant alpha-synuclein protein causes blockage in dopamine neurons, leading to their death and eventually Parkinson's disease. This finding may aid in the development of new treatments to slow or stop disease progression.
Researchers at Vollum Institute found that dopamine molecules are released from midbrain nerve cells in a targeted manner, traveling to receptors within milliseconds. The study's findings suggest new therapeutic targets for Parkinson's disease and substance abuse.
A study by OHSU found that methylphenidate, Ritalin, increases the effects of levodopa on dopamine levels, improving symptoms such as tapping and walking speeds. In contrast, paroxetine had no effect on physical symptoms but increased walking speed in Parkinson's patients.
Researchers are exploring neural transplantation as a potential treatment for Parkinson's disease, despite initial disappointing results from clinical trials. Further studies aim to improve the effectiveness of transplants and address concerns about side effects such as dyskinesias.
Researchers found high levels of COX-2 in dopamine neurons of Parkinson's patients, leading to cell death. Inhibiting the enzyme with a COX-2 inhibitor increased surviving neurons by up to 88%. The study suggests COX-2 inhibitors may slow disease progression and is being tested in new trials.
A new screening method uses glowing worms to test neuroprotective compounds, which may lead to new Parkinson's disease treatments. Researchers can selectively kill dopamine neurons in living worms using neurotoxins, and the green glow dims when they die.
Dr. Ted Fon, a renowned Parkinson's Disease researcher, has been awarded a significant grant by the Michael J. Fox Foundation to investigate the role of protein degradation in the disease. The grant aims to enhance understanding of parkin function and its potential impact on dopamine nerve cell death.
A new class of drugs may prevent neurodegenerative disorders by fortifying neurons before disease onset. Geldanamycin, a natural antibiotic, boosts molecular chaperone activity, protecting against alpha-synuclein toxicity in Parkinson's disease.
A Rutgers University researcher found that dopamine loss causes brain connections to reorganize, leading to impaired motor control. The study suggests that this permanent change may explain why current treatments fail to restore complex movements in Parkinson's disease patients.
Researchers have successfully transplanted embryonic stem cell-derived neurons into a rat model for Parkinson's disease, reducing disease symptoms and establishing functional connections. This breakthrough finding suggests that embryonic stem cells may be useful for treating PD and other brain diseases.
Researchers at Rush University Medical Center have identified the signal that instructs stem/progenitor cells to become dopamine neurons, a key step in treating Parkinson's disease. By cloning and transplanting these specific cells, the team hopes to develop new treatments for Parkinson's, Alzheimer's, and other diseases.
A study led by Kenneth Marek found that pramipexole slows dopaminergic neuronal degeneration compared to levodopa in early Parkinson's patients. Most patients will be treated with both medications, and further research is needed to assess the clinical impact of these findings.
Researchers found that nicotine prolongs the reward period by disabling the system that counterbalances its pleasant effects. This results in an enhanced ability to reinforce smoking behavior, making it challenging for people to quit despite the severe health consequences of tobacco use.
Researchers used C.elegans to study molecular mechanisms of dopamine neuron degeneration in Parkinson's disease. The study found that exposure to a neurotoxin, 6-OHDA, caused rapid death of dopamine neurons, and blocking dopamine transporter function eliminated the toxic effect.
Researchers found that mice fed a folate-deficient diet developed severe Parkinson-like symptoms, while those with adequate amounts of the vitamin protected their brain cells from damage. Folate deficiency may contribute to increased toxin-induced damage to dopamine-producing neurons.
A protective protein called a chaperone suppresses the toxicity of alpha-synuclein, a protein associated with Parkinson's disease. The study found that augmenting levels of Hsp70 corrected the deficit and overcame the toxic effect of loss of chaperone function.
A team of Penn researchers found that molecular chaperones can block the progression of neurodegenerative diseases like Parkinson's by preventing neuronal decay in Drosophila melanogaster. The study suggests that activating these molecules may be an effective approach to treating several human neurodegenerative diseases.
Researchers found that alcohol sensitizes dopamine and serotonin neurons, leading to excitotoxicity and neuronal damage. Brain-derived neurotrophic factor (BDNF) may protect against this excitotoxicity, suggesting a potential treatment for alcoholics undergoing withdrawal.